#United States #Phoenix #BioLab Holdings #Membrane Wrap #pressure ulcers

BioLab Holdings Publishes Promising Study on Membrane Wrap™

In a significant advancement for medical technology, BioLab Holdings, Inc., a Phoenix-based company dedicated to innovating tissue restoration, announced the publication of a pivotal real-world evidence study. This study evaluates the effectiveness of its Membrane Wrap™, a human amniotic tissue membrane, in treating complex pressure ulcers. The findings have been published in the peer-reviewed International Journal of Tissue Repair, marking a notable contribution to advanced wound care therapies.

Study Overview

The study, titled "Global Burden to Local Action: A Pilot Feasibility Study of Placental-Based Solutions for Complex Pressure Ulcers Using Real-World Evidence," contrasts the outcomes of patients treated with Membrane Wrap™ alongside standard care to those receiving only the standard care. Utilizing a multicenter retrospective matched-cohort design, the study analyzed deidentified electronic health record data from the U.S. Wound Registry and Intellicure database, incorporating patients from diverse healthcare environments across various geographic regions.

A total of 182 patients with pressure ulcers participated in the study, with half receiving Membrane Wrap™ in conjunction with standard treatment. The results highlighted that 63.7% of those treated with Membrane Wrap™ demonstrated healing or were classified as healed by the conclusion of the observation period. In contrast, only 48.4% of the patients who received standard care alone achieved similar outcomes.

Implications of Findings

This study’s results underscore the importance of clinical research in evaluating advanced wound care technologies. Marshall Medley, DO, the chief medical officer of BioLab Holdings and co-author of the study, noted that producing clinical evidence is crucial for understanding how these technologies function in real-world settings and in addressing the needs of varied patient populations. The increase in healing rates among patients treated with Membrane Wrap™ shows promising potential for improving patient outcomes in wound care.

Pressure ulcers remain a critical challenge in healthcare, particularly among older populations and individuals with multiple chronic conditions. Alarmingly, the global incidence of pressure ulcers has more than doubled between 1990 and 2021, signifying an urgent need for effective treatment options. By sharing insightful findings, BioLab Holdings is contributing to the discourse surrounding these healthcare challenges and the solutions necessary for improved patient care.

BioLab's Commitment to Clinical Evidence

Jaime Leija, president and CEO of BioLab Holdings, emphasized the importance of the study, framing it as a continuation of the company’s commitment to generating substantial clinical evidence for advanced wound care therapies. He noted that over a year ago, the company made a strategic decision to invest heavily in producing clinical and real-world data that would aid providers in making informed treatment choices.

The publication represents a milestone in BioLab's clinical research strategy, which is aimed at strengthening the evidence base for its Cellular, Acellular, and Matrix-like Products (CAMPs) portfolio. Building on this commitment, the company has commenced enrollment in the CAMPR-II trial, testing next-generation products Membrane Wrap Hydro™ and Microlyte™ in patients with diabetic foot ulcers and venous leg ulcers. Additionally, the BIOMOHS trial is slated to start enrollment following Institutional Review Board approval, and the CAMP RWE trial is currently in the statistical analysis phase.

Conclusion

The advancement of placental-based therapies in managing chronic pressure ulcers is vital, and BioLab Holdings' findings contribute valuable evidence to this emerging field. The study advocates for further prospective research, fortifying the argument that innovative solutions like Membrane Wrap™ are essential in addressing the pressing issue of pressure ulcers. With ongoing studies and a steadfast commitment to improving patient outcomes, BioLab Holdings is paving the way for enhanced wound care practices.

For more information on BioLab Holdings and their innovative products, visit biolabholdings.com.